Nautilus Biotechnolgy stock
NAUTNASDAQNautilus Biotechnolgy, Inc., HealthcareISIN US63909J1088
40Score 40 out of 100, Weak
Price and trend
62 / 100
Price history
+38% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 12% above it.
Since July 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 36).
The price is 40% below its 52-week high. Largest decline in 6 years: 97% (February 2021 to September 2025).
Chart figures for advanced users
- SMA 50$1.84
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$2.13
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)36
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$0.85
- The lowest closing price of the last twelve months.
- Resistance$3.95
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Nautilus Biotechnolgy, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $303.15M, is number 286 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 40 out of 100 (Weak): rank 540 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $86.58M, financial debt $26.74M.Stability 67
Weaknesses
- DilutionShare count up 49% since 2021.Capital allocation 18
- Volatile share priceVolatility 117% a year over the last 12 months.Stability 67
- Loss-makingLoss of $58.58M over the last 12 months.Fundamentals 17
Its standout strength is momentum, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 27 Oct 2026EPS reported −$0.12 (expected −$0.14)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 7.2% since 26 Oct 2026.
- Earnings per share
- −$0.49+5.4%
- Revenue
- $668.5K+24.7%
- Earnings per share
- −$0.49+7.2%
- Revenue
- $5.77M+11.7%
MEQIRI has stored the estimates since 26 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +31.6%Nautilus raised its 2026 revenue outlook, expecting revenue to exceed the prior guidance of approximately $500,000, and also expects fourth quarter revenue to grow sequentially from the third quarter.
“As a result, we now expect total 2026 revenue to exceed our prior outlook of approximately $500,000. Total operating expenses were $16.9 million for the third quarter of 2026, an increase of approximately 10% from $15.5 million in the prior year period.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $11.75M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- AH Equity Partners Bio II, L.L.C.Sale
2 Jun 2026, Major holder
- Shares
- 5,000,000
- Price
- $2.35
- Value
- $11.75M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Nautilus Biotechnolgy
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 40
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- AgomAb TherapeuticsAGMB $313.22M30
- AltimmuneALT $313.17M24
- Kyverna TherapeuticsKYTX $311.07M28
- Vicore Pharma HoldingVICO.ST $310.09M38
- Turn TherapeuticsTTRX $307.62M44
- MapLight TherapeuticsMPLT $301.31M32
- FormyconFYB.DE $293.75M30
- Heidelberg PharmaHPHA.DE $105.76M28
ETFs that hold Nautilus Biotechnolgy
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.00% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.00% | 0.30% | €4.28B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.